Today's RNS could be significant:

(strangely doesn't appear in MoneyAM's RNS lists!)

Here it is from the other place:

***************************************************

RNS Number:4181T
BioProjects International PLC
18 December 2003



BIOPROJECTS' MAIN INVESTMENT
PRODUCES DRAMATIC STUDY RESULTS

BioProjects International, the AIM-quoted company that invests in early-stage
biotechnology projects, today announces that the ViaLogy Corp, in which it has a
47.6 per cent stake, has completed a major research collaboration with its Swiss
partner, Zeptosens AG, which produced 'outstanding' results. The outcome is so
compelling that both companies have agreed to immediately initiate
commercialization.

The extensive research applied ViaLogy's Quantum Resonance Interferometry (QRI)
signal processing software to the planar waveguide (PWG) microarray technology
produced by Zeptosens AG of Switzerland. The study, using Zeptosens' high
sensitivity SensiChip microarray system, showed that QRI produced a 50-fold
improvement in the quantitation detection and a 10-fold reduction in data
variance.

This boost in performance opens the door for a level of in-depth information
detection and speed of screening in excess of any previously-known microarray
analysis. It will result in significant cost reductions as well as savings in
labour, time and information distortion.

"We are pleased with the outstanding results achieved by this collaboration with
Zeptosens," said Doug Lane, ViaLogy's CEO. "A 50-fold improvement is remarkable
and breaks new boundaries in detection and analysis."

The two companies will continue to integrate their technologies and next month
(January) ViaLogy plans to launch VMAxS, its ViaLogy Microarray Analysis
Service, which will be available to Zeptosens customers and others, on-line.

"We are delighted that ViaLogy has reached the stage where it is forming
Commercial alliances with such prestigious partners as Zeptosens," said
BioProjects' Chairman Jim Slater. "The technology is exciting and we believe it
will continue to make a real impact in the field of life sciences."

Further information from: Terry Bond, Managing Director, BioProjects
International.

Telephone 01235 834734 or mobile 07860 842756.
Email: terry.bond@bioprojects.com

***************************************************

Bioprojects' future is chiefly invested in this USA company (spun out from NASA). It is a compelling mix of leading edge computer and life sciences technology.

DYOR etc etc

Opening price 18/12/03 = 2.75p
RNS at 11.22am
Closing price 18/12/03 = 4.5p

http://www.bioprojects.com
http://www.vialogy.com
http://www.acolytebiomedica.com/index.htm
http://www.zeptosens.com/index2.html

Charts as follows:

The giant awakens atlast!

Rapid MRSA Testing A Step Closer To Reality


Major breakthrough in the fight against MRSA months away
In an unassuming complex of buildings in rural Wiltshire, development of a diagnostic platform that could save hundreds of lives and millions of pounds is well under way.

Acolyte Biomedica Ltd is in the final development phase of BacLite, a rapid and cost-effective MRSA screening test which will reduce the time taken to diagnose MRSA from up to five days, to under five hours. As an aid to reducing the spread of MRSA among hospital staff and patients, BacLite could potentially save hundreds of lives and millions of pounds for the NHS each year.

The BacLite MRSA test detects the organism directly from nasal swabs and uses a combination of traditional microbiology techniques familiar to biomedical scientists and therefore making it applicable to most microbiology laboratories. These techniques are combined with the unique sensitivity of adenylate kinase (AK) bioluminescence to enable such rapid results. In-house trials have shown high levels of sensitivity and with reagent development complete, Acolyte scientists are now finalising system optimisation/ design.

Coming to the aid of overstretched biomedical scientists, the BacLite MRSA test will be easier to interpret than current techniques which require a high level of technical training and judgement. Commenting on the tests potential Dr Bill Mullen, the company CEO, said By avoiding the need for complex technologies the test can be performed in the local laboratory rather than sent to a reference service. This means testing speed can be exploited to the full. We are really excited about BacLites potential and look forward to making a significant contribution to the control of this serious infection.

Acolyte Biomedica plan to launch BacLite in the second quarter of 2005.

For futher information please contact:
Product enquiries
Glynn Colebrook
Commercial Manager
Acolyte Biomedica
t: +44 (0)1980 551320
e: gcolebrooke@acolytebiomedica.com

Media enquiries
David Robinson
Alto Marketing Limited
t: +44 (0)1489 557672
e: davidr@alto-marketing.com

Just wondered if anybody out there watching this company ang got any opinions